Mold and Mycotoxins: The Hidden Puzzle Piece in Chronic Illness
What I have come to understand from my own story, from the biology of mycotoxins, and from years of clinical work. And why this topic could be the missing piece for many people with chronic illness.
Diagnoses such as irritable bowel, asthma, migraine, depression or "exhaustion without a clear cause". Countless examinations, blood values "fine", imaging unremarkable, and yet you still do not feel well.
From my perspective, mold is a topic that has so far received little attention, one that can play a role in chronic complaints but is rarely checked systematically in routine diagnostics.
How I label evidence in this cluster
A large part of what we know about mycotoxin effects comes from in vitro cell experiments and in vivo animal models. Human studies exist but are limited. For each source we transparently mark the level of evidence.
Why mold is different from "normal" toxins
Heavy metals are substances. They can deposit in the body but do not multiply. Mold is a living organism. That makes it fundamentally different. More than 400 different mycotoxins have been described, and they can be stored in fatty tissue, in organs and in the nervous system.
Mold does not have to be visible to have an effect. It can sit behind wallpaper, in mattresses, in air conditioning units, in basements and in water-damaged building components. What you cannot see can still burden your system. This is not esotericism, it is the reality of aerosols and microparticles that spread through the air we breathe and through skin contact.
My mother's story
My mother had had irritable bowel syndrome and sigmoid diverticulitis for years. Then came a sudden, massive deterioration. Her abdomen was extremely bloated, all day long. A lively woman became a person with inner restlessness, states of anxiety, and the feeling of permanently "no longer being herself".
Suddenly she no longer knew what she had eaten two days earlier. She used to be able to tell you where she had stored something a year ago. We thought of parasites, negative. Always the same diagnosis: irritable bowel syndrome.
The deeper I dug, the more this term annoyed me. Because it is often given when one should really say: "We do not know what is going on." Only when I went through the home environment systematically did I find what had been overlooked until then.
Clarification: I cannot claim an isolated causality, but I document the temporal connection between remediation of the environment, targeted mycotoxin-oriented treatment, and the improvement of my mother's symptoms over the following months.
The eight systems that mycotoxins can attack
What is insidious about mold is not only that it can make you ill, but how it does so. It does not attack a single organ. It attacks several systems in parallel. This explains why patients with this picture are sent from one specialist to the next without any single finding explaining everything.
Nervous system: brain fog, anxiety, inner restlessness
Several mycotoxins act neurotoxically in laboratory models. Ochratoxin A can cross the blood-brain barrier and has been linked to Alzheimer-like disease mechanisms. In laboratory models, T-2 toxin triggers oxidative stress and neuroinflammation. Patients describe it as "fog in the head".
Immune system: between exhaustion and constant alarm
Mycotoxins show a bidirectional immune effect. At low doses they can activate inflammatory reactions. At high doses or with long exposure they suppress the immune system. Both directions can make you ill.
Mitochondria: when the power plants fail
Many of the mycotoxins studied can damage mitochondria through a similar mechanism (shown mostly in vitro and in vivo): ROS overproduction, collapse of the membrane potential, cell death. The body tries to neutralise with glutathione, but the store empties faster than it can be refilled.
Cancer risk: what is officially established
Aflatoxin B1 is classified by the IARC as Group 1, that is, an established human carcinogen. AFB1 is converted in the liver into a highly reactive epoxide, binds to the DNA and produces a specific TP53 mutation. Other mycotoxins such as ochratoxin A are in IARC Group 2B, not established as carcinogenic in humans but tumour-inducing in animal experiments.
Hormone system: mycotoxins as false estrogens
Zearalenone is one of the most potent known myco-estrogens. The tissue "reads" an estrogen message, but not from real estrogen. The lab measures normal. Yet the body behaves as in estrogen dominance. Cycle disturbances, intensified PMS, heavier bleeding, breast tenderness, infertility without an explainable cause can be the consequence.
Gut and barriers: the gateway
Deoxynivalenol can damage the tight junction proteins in cell and animal models, the molecular "rivets" that hold the intestinal epithelial cells together. The result: leaky gut, an increased permeability that lets bacterial components and toxins into the blood. More in the leaky gut spoke.
Skin and mucous membranes
Itchy, shifting rashes. Burning eyes. Chronic sinusitis. In 2009 the WHO estimated that around 21 percent of current asthma could be attributable to indoor dampness and mold.
Circulation, temperature, energy
Racing heart without a finding. Dizziness when standing up. Temperature chaos between feeling cold and hot flushes. Daytime crashes in which all energy is suddenly gone, as if someone had flipped a switch.
The five most important mycotoxins in profile
The carcinogen
IARC Group 1, established human carcinogen. Main producer Aspergillus flavus. Hepatotoxic, induces a specific TP53 mutation in the liver. Main source worldwide: contaminated foods (peanuts, maize).
The kidney and brain toxin
IARC Group 2B. Main producers Penicillium and Aspergillus. Nephrotoxic, neurotoxic, can cross the blood-brain barrier. Main sources of exposure are contaminated grain, coffee, dried fruit.
The immune system killers
Main producer Fusarium, indoors also Stachybotrys (black mold). Highly potent immunosuppressive and protein-synthesis inhibiting. DON additionally damages the gut barrier. Particularly relevant in water damage.
The myco-estrogen
Main producer Fusarium. Binds to estrogen receptors, can act in an estrogen-like way. In women cycle disturbances can occur, in men reproductive effects have been described. Clearly documented in animal models, human data limited.
The common denominator: Cell Danger Response
Robert Naviaux, Neil Nathan and other researchers have formulated an approach that connects the seemingly different clinical pictures that arise with mycotoxin burden. The concept is called Cell Danger Response (CDR). A cell that is repeatedly or permanently exposed to toxic or infectious burden can switch into a protective mode. This mode is useful for short crises, but becomes pathological when it is not switched off again.
Naviaux describes the Cell Danger Response as an evolutionarily conserved cellular protective response. When cells remain chronically in CDR stages, the typical multi-system complaints arise that are seen more frequently in mold, Lyme, MCAS and MCS patients. Therapy aims to enable a reset of the CDR.
The four cPNI lenses on mold burden
1. Nervous system
Neurotoxic mycotoxins such as OTA and T-2 take centre stage. Clinically, brain fog, sleep disturbances and autonomic dysregulation dominate. Vagus nerve tone is often pathologically reduced. The complaints are not "imagined", they have a measurable basis.
2. Immune system
Mast cell activation, low-grade systemic inflammation, Th1/Th2 shift. MCAS and histamine intolerance are common clinical consequences. Elevated markers such as CRP, IL-6, tryptase can point to it, but are not conclusive.
3. Metabolism
Mitochondrial dysfunction, glutathione depletion, methylation bottleneck. Patients often show symptoms such as chronic fatigue, cold hands and feet, exercise intolerance. Mitochondrial function can be mapped through specialised laboratory diagnostics.
4. Hormone system
Myco-estrogens such as zearalenone can shift the hormonal balance. The HPA axis is often permanently activated with cortisol dysrhythmia. Thyroid conversion disturbances occur. The link to mold exposure is rarely made in conventional endocrinology.
The treatment pyramid: order is everything
In no other therapy is the order as important as with mold. Those who attack too strongly too early can get worse. Those who stay too cautious achieve nothing. The following staging has proven itself clinically.
Stop the exposure
Without a mold-free environment everything else is limited. Anyone still sleeping in a contaminated home is cleaning with the tap turned on. The first measure is always analysis of the environment and remediation or relocation.
Bind mycotoxins at a tolerable dose
Preparation: regular bowel movements, sufficient fluids, stable sleep. Only then come binders such as activated charcoal, chlorella, bentonite, cholestyramine. Always in mini-doses, slowly increased. Cholestyramine is prescription-only; its use for mycotoxin burden is off-label and exclusively under medical prescription and supervision. More in the detoxification spoke.
Stabilise gut, liver, lymph
Gut: a fibre-rich, low-inflammation diet, targeted probiotics. Liver: the central transformation organ, phase 1 and phase 2 support. Lymph and kidney: gentle movement, sufficient water, breathwork, dry brushing where appropriate.
Address mold in the body
Only once the earlier stages are stable: antifungal strategies, individually tailored. As little "sledgehammer" as possible, as targeted as necessary. The aim is not primarily to kill fungi, but to restore system balance.
Why do-it-yourself attempts can be dangerous
Mold is not something for self-experiments following a YouTube protocol. Your body is not a bucket that you "rinse out", but a highly complex system. Therapy without medical supervision can worsen rather than improve things.
The three most common mistakes in do-it-yourself attempts:
- Treating with antifungals too early: fungi release mycotoxins as they die. If the body is not prepared, this can increase the burden in the short term.
- Binders in high doses: chlorella, activated charcoal and zeolite at too high a starting dose can trigger severe reactions.
- "Pushing" detoxification without an elimination pathway: if liver, gut and kidney are overwhelmed, toxins are not excreted but redistributed within the body.
"I am not broken. My system was overloaded."
This reframe changes everything. Anyone who understands that many chronic complaints can have a measurable cause stops blaming themselves. "What is wrong with me?" becomes "What overloaded my system?" That question is therapeutically fruitful.
Three levers if you suspect mold
Go through your home and work history honestly
The last 10 to 20 years. Were there water damages, damp basements, leaking roofs? Did the onset of complaints coincide in time with a move or a water situation? Anyone who feels noticeably better on holiday and worse again at home has an important diagnostic clue.
Seek a specialised history-taking
Standard care has so far rarely treated this topic as its own focus; a specialised environmental medicine history can help here as a complement. An integrative practice with a focus on environmental medicine, functional diagnostics and cPNI can categorise the symptoms systematically. A complete history takes time, but it is the most valuable examination.
Do not detox rashly, but proceed in a structured way
Patience is part of the therapy. Anyone who wants too much too fast risks deterioration. A good therapy begins with stabilisation, then exposure, then a targeted approach. That is slower, but more sustainable.
Frequently asked questions about mold and mycotoxins
What are mycotoxins?
Mycotoxins are toxic metabolic products that molds produce as defensive weapons. More than 400 different mycotoxins have been described. The most important ones indoors are ochratoxin A, trichothecenes such as T-2 and deoxynivalenol, aflatoxins and zearalenone. They can be taken up through the airways, the gut or the skin.
Can molds trigger chronic illness?
Several mycotoxins are described as neurotoxic, immunomodulating, hepatotoxic and endocrine active in in vitro models and animal studies. Human studies are limited but growing. In a subset of chronic complaints without a clear cause, mold burden could be a previously overlooked co-factor. Clinical observations point to links with mast cell activation, histamine intolerance, ME/CFS and irritable bowel.
Which symptoms may point to mold?
Brain fog, chronic fatigue, shifting muscle and joint pain, digestive complaints, chronic sinusitis, asthma that flares in certain rooms, mood swings, paradoxical reactions to well-meant therapies. Suspicion rises when complaints improve on holiday and worsen at home.
How is mold burden diagnosed?
Diagnostics combine history-taking, an analysis of the environment (home and work history), basic labs, a urine mycotoxin profile in specialised laboratories and, where appropriate, a building biology assessment. No single method is diagnostically conclusive, the overall picture is what counts. More in the mycotoxin test spoke.
Which mycotoxins are particularly relevant?
Ochratoxin A can act neurotoxically and nephrotoxically. Aflatoxin B1 is the only mycotoxin classified as an established human carcinogen (IARC Group 1). Trichothecenes such as T-2 toxin are considered highly potent immunosuppressants. Zearalenone can act in an estrogen-like way. Deoxynivalenol can damage the gut barrier. Most other mycotoxins are less well researched.
How is mold approached therapeutically?
The order is decisive: first stop the exposure, then gently bind mycotoxins, then stabilise gut/liver/lymph, then specifically address mold in the body. Binders such as cholestyramine or activated charcoal, glutathione support, mitochondrial therapy and individual lifestyle adjustment are building blocks. Therapy without medical supervision is not recommended.
Is mold connected to other chronic illnesses?
Clinical observations and some studies suggest links to mast cell activation syndrome (MCAS), multiple chemical sensitivity (MCS), ME/CFS, fibromyalgia, irritable bowel syndrome, histamine intolerance and leaky gut. Neil Nathan's concept of the "Cell Danger Response" describes the shared mechanism.
When should I think about mold?
When you have a long history of suffering with many unsuccessful treatment attempts, when you have had visible mold or water damage in your environment, when complaints are worse at home and better on holiday, when you show paradoxical reactions to supposedly "good" therapies. These clues justify a specialised medical assessment.
30 spokes for the cluster "Mold and Mycotoxins"
- Spoke 1: Histamine intolerance and mycotoxins
- Spoke 2: Fibromyalgia and mold
- Spoke 3: Irritable bowel and mycotoxins
- Spoke 4: Leaky gut and mycotoxins
- Spoke 5: Mold, what to do
- Spoke 6: Brain fog symptoms
- Spoke 7: Brain fog causes
- Spoke 8: Chlorella and mycotoxins
- Spoke 9: MCAS and mold
- Spoke 10: Chronic sinusitis and mold
- Spoke 11: Detox done right instead of wrong
- Spoke 12: Mitochondria and mycotoxins
- Spoke 13: Zeolite for mycotoxins
- Spoke 14: Mold symptoms overview
- Spoke 15: Oxidative stress and mycotoxins
- Spoke 16: Candida and mold
- Spoke 17: Mold in the home
- Spoke 18: Aspergillus
- Spoke 19: Bentonite as a binder
- Spoke 20: Cholestyramine for mold
- Spoke 21: Chronic fatigue and mold
- Spoke 22: Aflatoxin B1 in detail
- Spoke 23: Mold allergy vs toxicity
- Spoke 24: Mycotoxin basics
- Spoke 25: Eliminating mycotoxins
- Spoke 26: Glutathione deficiency and detox
- Spoke 27: Ochratoxin A
- Spoke 28: Realistic mold remediation
- Spoke 29: Mold in pregnancy
- Spoke 30: Zearalenone and hormones
The connection to my other areas of focus
Mold burden rarely comes in isolation. It destabilises the gut, blocks the detoxification pathways for heavy metals, and can burden the nervous system so much that conventional treatments do not take hold.
Mycotoxins damage tight junctions and block gut motility. Irritable bowel and leaky gut are common consequences.
Mold blocks glutathione and detoxification enzymes that are needed for heavy metal elimination. The two burdens reinforce each other.
Inflammation and mitochondrial damage from mycotoxins can trigger or intensify depressive symptoms.
Neuroinflammation from a mycotoxin load can limit standard antidepressant therapy. Ketamine can be a tool when the underlying toxin load is addressed.
Sources and evidence classification
For many mycotoxin effects the main evidence comes from in vitro cell experiments and in vivo animal models. Human studies exist but are limited. For each study we transparently mark the level of evidence. What we describe as biologically plausible is not in every case backed by a large randomised human study.
- Hurraß J et al. AWMF S2k guideline 161/001: Medical and clinical diagnostics for indoor mold exposure. AWMF. 2023. register.awmf.org/161-001 [Official document, guideline]
- WHO Guidelines for Indoor Air Quality: Dampness and Mould. World Health Organization. 2009. who.int [Official document]
- Nathan N. Toxic: Heal Your Body from Mold Toxicity, Lyme Disease, Multiple Chemical Sensitivities, and Chronic Environmental Illness. Houndmills. 2018. [Clinical review]
- Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014. doi:10.1016/j.mito.2013.08.006 [Mechanism review]
- Obafemi TA et al. Ochratoxin A neurotoxicity mechanisms and therapeutic strategies. Toxicology. 2023. doi:10.1016/j.tox.2023.153491 [In vitro, in vivo, mechanism review]
- Wang Y et al. T-2 toxin neurotoxicity and signaling pathways. Mycotoxin Research. 2024. doi:10.1007/s12550-023-00505-2 [In vivo, review]
- Ratnaseelan AM et al. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clinical Therapeutics. 2018. doi:10.1016/j.clinthera.2018.05.004 [Review]
- Chang C, Gershwin ME. The Science Behind Mold and Human Illness. Clin Rev Allergy Immunol. 2019. doi:10.1007/s12016-019-08741-0 [Review]
- Ostry V et al. Mycotoxins as human carcinogens, IARC classification update. Mycotoxin Research. 2017. doi:10.1007/s12550-016-0265-7 [Official document, review]
- Balló A et al. Zearalenone estrogen-like effect. Int J Mol Sci. 2023. doi:10.3390/ijms24021578 [In vitro, in vivo, mechanism review]
- Fan L et al. Deoxynivalenol-induced gut microbiome interaction. Environ Int. 2024. doi:10.1016/j.envint.2024.108450 [In vivo, mechanism review]
- Ma J et al. Indoor dampness, mold, and depression: a systematic review. Environ Health. 2025. doi:10.1186/s12940-024-01154-3 [Systematic review, human]
- Wang JS et al. NovaSil Clay-Phase IIa randomized controlled trial for aflatoxin reduction. Food Addit Contam. 2008. doi:10.1080/02652030701567467 [RCT, human]
This article serves general information purposes and does not replace individual medical advice, diagnosis or treatment. Some of the substances mentioned are prescription-only or are used outside their approval (off-label); their use belongs exclusively in medical prescription and supervision. Where anthroposophic or experience-based methods are mentioned, they are based in part on clinical tradition and are not in all respects backed by large randomised studies. Results are individual and are not a guaranteed treatment outcome. Author: Shukri Jarmoukli, ViveCura practice, Skalitzer Straße 137, 10999 Berlin.